CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
骨髓增生异常综合征（MDS）中新兴的免疫肿瘤靶点
英文原题：Emerging immuno-oncology targets in Myelodysplastic Syndromes (MDS).
查看英文原题
Emerging immuno-oncology targets in Myelodysplastic Syndromes (MDS).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
骨髓增生异常综合征（MDS）的免疫治疗方法通常分为2类：靶向免疫效应细胞并增强或引导抗白血病效应的疗法，以及靶向MDS祖细胞本身免疫标志物的疗法。前者的例子包括免疫检查点抑制剂、免疫调节疗法和疫苗等，而后者的例子包括抗体-药物偶联物疗法和裸抗体；而双特异性抗体和修饰T细胞（如CAR-T 疗法）则桥接这两种治疗模式。在本综述中，我们将讨论上述疗法的原理、迄今为止的临床结果以及潜在的未来研究方向。
展开英文摘要原文
Approaches to immunologic therapies in myelodysplastic syndromes (MDS) have generally fallen into 2 categories: therapies that target immune effector cells and enhance or direct an antileukemic effect, and therapies which target immunological markers on MDS progenitors themselves.
Examples of the former include immune checkpoint inhibitors, immunomodulatory therapies, and vaccines, among others, while examples of the latter include antibody-drug conjugate therapies and naked antibodies; while bispecific antibodies and modified T-cells (such as CAR-T therapies) bridge both therapeutic modalities. In this review, we will discuss the rationale for the above therapies, clinical results to date, and potential future directions for investigation.
论文信息
- 作者
- Mann M、Brunner AM
- 第一作者单位
- Boston University School of Medicine, Department of Medicine, Boston, Massachusetts.United States
- 通讯作者单位
- Massachusetts General Hospital Cancer Center, Leukemia Program, Harvard Medical School, Boston, Massachusetts. Electronic address: abrunner@mgh.harvard.edu.United States
- 文献类型
- 美国 NIH 资助研究 · 非美国政府资助研究 · 综述
- 期刊
- Current problems in cancer2022 Feb
- 原文标识
- PubMed 34980485 · DOI 10.1016/j.currproblcancer.2021.100824
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →